New combo therapy aims to halt liver damage from hepatitis b
NCT ID NCT07183293
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This study tests whether adding peginterferon alfa-2b to standard antiviral drugs can improve liver health in people with compensated hepatitis B cirrhosis. About 30 adults will be randomly assigned to receive either the combination or antivirals alone. The main goal is to see if the combination leads to better liver tissue scores and lowers the risk of liver cancer or liver failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV-RELATED LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, China
Contact
-
Zhongshan Hospital Affiliated to Xiamen University
Xiamen, China
Contact
Conditions
Explore the condition pages connected to this study.